Close menu




October 15th, 2020 | 13:16 CEST

Bayer, Triumph Gold, BioNTech - decisive phase!

  • Investments
Photo credits: pixabay.com

Almost everyone knows the philosophies proclaimed by the great and wise stock market gurus. “Never try catch a falling knife" or "buy on the sound of cannons, sell on the sound of trumpets”. What is true? In the case of Bayer, after the Monsanto disaster, possibly higher than planned fines and a cracking profit warning, one might think that everything has already been priced in. However, it is still not known how and when the Monsanto disaster will end. The fact is, there are other, more appealing papers at the moment ...

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA8968121043 , DE000BAY0017 , US09075V1026

Table of contents:


    Trust from Switzerland

    Despite a stable market environment, Bayer continued to move south. Dropping below the EUR 45.00 mark marked a 5-year low. The Leverkusen-based Company was encouraged by the Swiss, of all countries. The major Swiss bank UBS left the rating for Bayer at "Buy" with a price target of EUR 85.00. Despite the announced dividend cut, UBS does not necessarily see Bayer as lacking money. The analyst cites as the reason that the pharmaceutical giant only issued a bond with a volume of EUR 6 billion in August.

    Besides, it would also be possible to generate cash by selling shares. Given the profit warning that was issued shortly before the issuing of the bond and the continuing uncertainty about possible fines, caution is still necessary at the current level.

    Before all-time high

    Everything else how bad things are going at the moment for the Mainz-based developer of a vaccine against the pandemic pathogen. The exploding COVID-19 infection figures are another reason why the Company is on everyone's lips.

    The vaccine candidate BNT162, developed in cooperation with Pfizer, is currently being tested in final clinical trials. About 37,000 participants in the study have already received vaccinations, 28,000 have received two doses. There are 120 sites worldwide involved in this clinical study.

    From a chartist's point of view, the upward trend, which has been in evidence since October 2019 and currently stands at EUR 55.00, is fully intact. If the positive news continues in the coming weeks, it is only a matter of time before the EUR 100.00 mark is reached and broken through.

    Opportunity after consolidation

    The stock of the Canadian gold explorer Triumph Gold also corrected sharply. In August 2020, the share price was at CAD 0.48, but now almost half of it is at CAD 0.25. The reasons for the fall to the south are, on the one hand, the weakening gold price and, of course, the still too weak sales due to the Company's high profile, this of course results in increased volatility, but also a great opportunity.

    Triumph Gold Corp. is a growth-oriented Canadian gold exploration and development company with a large land package in the mining-friendly Yukon. The Company's flagship project, Freegold Mountain, is located in the Dawson Range. It hosts three NI 43-101 compliant mineral deposits. It covers an extensive area of the Big Creek Fault Zone, a structure similar to epithermal gold and silver mineralization, and gold-rich porphyry copper mineralization.

    Successful Exploration Program

    As of September 18, 2020, Triumph Gold announced that it had completed the fully funded exploration program PR20-07. The program included minor trenching and reconnaissance sampling, as well as 2,068 meters of diamond drilling. The partially near-surface surveys are now in the evaluation and analysis phase. According to Jesse Halle, Vice President of Exploration, several of the reconnaissance samples collected indicate that gold mineralization is much more widespread than previously thought. As a result, the 2021 exploration program is to expand.

    Also noteworthy is the Canadian shareholder list, which includes known names. In addition to the Zijn Mining Fund, industry leader Newmont Mining is also a shareholder.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.

    Read

    Commented by Carsten Mainitz on May 10th, 2022 | 10:39 CEST

    Zalando, Aspermont, SAP - Corona and back, the stock rebound is coming!

    • Digitization
    • Investments
    • Technology

    What would society and the economy look like without digitization? The Internet, software and smartphones have become a matter of everyday life and form the basis for communication and interaction. Corona has been an accelerator in many ways. On the other hand, pandemics and war clearly show us the limits of supposedly predictable growth with scarcity prices and supply chain disruptions. At a reduced price level, it is worth looking at "digitization stocks" that offer good opportunities.

    Read

    Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

    Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

    • Biotechnology
    • Pharma
    • Investments

    Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

    Read